Mojisola Adeyeye, director-general (DG) of the National Agency for Food and Drug Administration and Control (NAFDAC), says manufacturers will get incentives to develop paediatric medicines.
Adeyeye spoke in Lagos on Thursday at a press conference organised to outline the agency’s focus for 2025.
She said the agency would focus on five strategic pillars to safeguard the health of Nigerians.
“This realisation has sharpened my focus on how to strategically work towards continued strengthening of the regulatory system as a needed path toward safeguarding the health of the nation.”
She added that NAFDAC will continue to unlock the value chain by strengthening the industry with a focus on access to quality regulated products.
The DG said the agency would pay more attention to the safety and quality of regulated products for maternal, newborn, and child health and nutrition.
She said this would help to prevent postpartum haemorrhage and maternal deaths to drastically reduce child morbidity. “Great emphasis will be placed on paediatric antimalarials and antibiotics.
“Manufacturers will be incentivised to develop paediatric medicines and handhelds toward achieving WHO prequalification,” she said.
Adeyeye noted that the agency is “extremely understaffed.”. “The number of staff that an agency has or should have depends on the population of the country because it is easier to regulate a country with one million than a country with 300 million people.
“I’m just giving an example based on our population; we are supposed to have nothing less than 10,000 staff; we have about 2,000 right now.
“We burn candles on both ends, overstress ourselves because we have to safeguard the health of Nigerians. We are not asking for 10,000 staff now; we are just asking for double or triple what we currently have,” she said.